Century Therapeutics (NASDAQ:IPSC) versus BioStem Technologies (OTCMKTS:BSEM) Financial Contrast

Century Therapeutics (NASDAQ:IPSC) and BioStem Technologies (OTCMKTS:BSEM) are both small-cap healthcare companies, but which is the better investment? We will contrast the two businesses based on the strength of their valuation, risk, earnings, analyst recommendations, dividends, institutional ownership and profitability.

Risk and Volatility

Century Therapeutics has a beta of 1.67, meaning that its share price is 67% more volatile than the S&P 500. Comparatively, BioStem Technologies has a beta of 0.17, meaning that its share price is 83% less volatile than the S&P 500.

Insider & Institutional Ownership

50.2% of Century Therapeutics shares are held by institutional investors. 2.4% of Century Therapeutics shares are held by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock will outperform the market over the long term.

Profitability

This table compares Century Therapeutics and BioStem Technologies’ net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Century Therapeutics	N/A	-49.51%	-38.09%
BioStem Technologies	N/A	N/A	N/A

Valuation & Earnings

This table compares Century Therapeutics and BioStem Technologies”s revenue, earnings per share and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Century Therapeutics	$109.16 million	2.19	-$9.58 million	($0.93)	-1.42
BioStem Technologies	$292.21 million	0.15	-$28.70 million	($1.60)	-1.54

Century Therapeutics has higher earnings, but lower revenue than BioStem Technologies. BioStem Technologies is trading at a lower price-to-earnings ratio than Century Therapeutics, indicating that it is currently the more affordable of the two stocks.

Analyst Ratings

This is a breakdown of current ratings and target prices for Century Therapeutics and BioStem Technologies, as provided by MarketBeat.com.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Century Therapeutics	1	2	4	0	2.43
BioStem Technologies	0	1	0	1	3.00

Century Therapeutics presently has a consensus price target of $4.75, suggesting a potential upside of 259.85%. BioStem Technologies has a consensus price target of $9.00, suggesting a potential upside of 264.37%. Given BioStem Technologies’ stronger consensus rating and higher possible upside, analysts clearly believe BioStem Technologies is more favorable than Century Therapeutics.

Summary

Century Therapeutics beats BioStem Technologies on 8 of the 14 factors compared between the two stocks.

About Century Therapeutics

Century Therapeutics, Inc., a biotechnology company, engages in the development of genetically engineered allogeneic cell therapies for the treatment of solid tumor and hematological malignancies. Its lead product candidate is CNTY-101, an allogeneic, induced pluripotent stem cells (iPSCs)-derived chimeric antigen receptors (CAR)-iNK cell therapy, under Phase 1 trials targeting CD19 for relapsed, refractory B-cell lymphoma. The company is also involved in the development of CNTY-102, a bi-specific CD19 + CD22 CAR-iT product candidate for relapsed, refractory B-cell lymphoma and other B-cell malignancies; and CNTY-107, a Nectin-4 CAR-iT targeted product candidate for Nectin-4 positive solid tumors. In addition, it has a strategic collaboration with Bristol-Myers Squibb Company to develop and commercialize up to four iNK or iT programs, including CNTY-104, a multi-specific collaboration program targeting acute myeloid leukemia; and CNTY-106, a multi-specific collaboration program for multiple myeloma. The company was incorporated in 2018 and is headquartered in Philadelphia, Pennsylvania.

About BioStem Technologies

BioStem Technologies, Inc., a life sciences corporation, focuses on discovering, developing, and producing pharmaceutical and regenerative medicine products and services. It develops various biologic stem cell based alternative products, as a treatment for ailments, such as joint pain, tendon and ligament injuries, neurodegenerative, and autoimmune diseases. The company is also engages in the repackaging and distribution of active pharmaceutical ingredients and other pharmaceutical compounding supplies; and develops and markets nutraceutical products under the Dr. Dave's Best and Nesvik Organics brands, as well as other non-proprietary products in the United States and internationally. The company sells products through e-commerce platforms. BioStem Technologies, Inc. was incorporated in 2006 and is based in Pompano Beach, Florida.